Omeros Corporation

Equities

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-21 pm EDT			5-day change	1st Jan Change
3.97 ^USD	+0.38%		-2.22%	+21.41%

Jun. 12	Omeros Corporation Announces Executive Changes	CI
Jun. 03	Omeros Corporation announced that it expects to receive $92.1 million in funding	CI

Omeros Corporation Appoints Thomas F. Bumol to Board of Directors

February 12, 2019 at 08:30 am EST

Omeros Corporation announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director of the recently established Allen Institute for Immunology and former longtime senior executive at Eli Lilly and Company.

Latest news about Omeros Corporation

Omeros Corporation Announces Executive Changes	Jun. 12	CI
Omeros Corporation announced that it expects to receive $92.1 million in funding	Jun. 02	CI
Health Care Flat as Momentum Wanes -- Health Care Roundup	May. 16	DJ
Transcript : Omeros Corporation, Q1 2024 Earnings Call, May 15, 2024	May. 15
Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	May. 15	CI
Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	Apr. 01	CI
Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	Apr. 01	CI
Omeros Swings to Q4 Net Loss; Q1 Outlook Set	Apr. 01	MT
Omeros Corporation Provides Earnings Guidance for the First Quarter of 2024	Apr. 01	CI
Transcript : Omeros Corporation, Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Omeros Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase	Feb. 01	MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	Feb. 01	MT
Omeros Corporation(NasdaqGM:OMER) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Transcript : Omeros Corporation, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Omeros Corporation authorizes a Buyback Plan.	Nov. 08	CI
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting	Nov. 02	CI
Novartis drug candidate scores interim win in rare kidney disease trial	23-10-30	RE
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer	23-10-19	CI

Chart Omeros Corporation

Duration

Period

More charts

Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Companyâs lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.97

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OMEROS CORPORATION	+21.41%	230M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
ARGENX SE	+8.24%	23.61B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-16.19%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B

Bio Therapeutic Drugs